MetLife Investment Management’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.44M | Buy |
74,967
+2,779
| +4% | +$90.3K | 0.01% | 908 |
|
|
2025
Q1 | $2.73M | Sell |
72,188
-2,315
| -3% | -$87.4K | 0.01% | 898 |
|
|
2024
Q4 | $6.1M | Buy |
74,503
+6,670
| +10% | +$546K | 0.03% | 452 |
|
|
2024
Q3 | $7.75M | Buy |
67,833
+4,866
| +8% | +$556K | 0.04% | 330 |
|
|
2024
Q2 | $4.75M | Buy |
62,967
+8,970
| +17% | +$677K | 0.03% | 511 |
|
|
2024
Q1 | $3.69M | Buy |
53,997
+4,726
| +10% | +$323K | 0.02% | 660 |
|
|
2023
Q4 | $3.09M | Hold |
49,271
| – | – | 0.02% | 751 |
|
|
2023
Q3 | $2.51M | Buy |
49,271
+826
| +2% | +$42.1K | 0.02% | 797 |
|
|
2023
Q2 | $2.42M | Buy |
48,445
+10,869
| +29% | +$543K | 0.02% | 856 |
|
|
2023
Q1 | $1.41M | Hold |
37,576
| – | – | 0.01% | 1054 |
|
|
2022
Q4 | $1.8M | Buy |
37,576
+10,053
| +37% | +$482K | 0.01% | 943 |
|
|
2022
Q3 | $661K | Hold |
27,523
| – | – | 0.01% | 1436 |
|
|
2022
Q2 | $599K | Buy |
27,523
+3,834
| +16% | +$83.4K | ﹤0.01% | 1537 |
|
|
2022
Q1 | $572K | Buy |
23,689
+8,743
| +58% | +$211K | ﹤0.01% | 1688 |
|
|
2021
Q4 | $356K | Hold |
14,946
| – | – | ﹤0.01% | 1697 |
|
|
2021
Q3 | $379K | Hold |
14,946
| – | – | ﹤0.01% | 1695 |
|
|
2021
Q2 | $336K | Buy |
14,946
+3,238
| +28% | +$72.9K | ﹤0.01% | 1812 |
|
|
2021
Q1 | $231K | Buy |
11,708
+3,846
| +49% | +$76K | ﹤0.01% | 1977 |
|
|
2020
Q4 | $209K | Hold |
7,862
| – | – | ﹤0.01% | 1961 |
|
|
2020
Q3 | $388K | Buy |
+7,862
| New | +$388K | ﹤0.01% | 1503 |
|